Who Buys Quinine from India — 468 Importers Behind a $19.3M Market

The importation of Quinine from India involves a diverse array of buyers, each falling into specific categories:

1. Distributors: Entities like ALLOGA UK (United Kingdom) and PROVET SARLU (Madagascar) function as intermediaries, supplying Quinine to various healthcare providers. Their purchasing patterns are characterized by bulk orders to maintain a steady supply chain, ensuring product availability for their clients.

2. Government Procurement Agencies: Organizations such as UNICEF BANGUI (Central African Republic), UNICEF SOUTH SUDAN (South Sudan), and DIRECTION GENERALE DE LA CAMEBU (Burundi) procure Quinine for national healthcare programs. Their procurement is typically conducted through formal tender processes, emphasizing transparency and cost-effectiveness. These agencies often place large, periodic orders aligned with national health initiatives and budget cycles.

3. Contract Manufacturers: Companies like STRIDES PHARMA UK LTD and STRIDES PHARMA UK LIMITED (both United Kingdom) are involved in the manufacturing and supply of pharmaceutical products. Their procurement of Quinine is likely intended for formulation into finished dosage forms, which are then distributed to various markets. Their purchasing behavior is driven by production schedules and market demand forecasts.

4. Retail Chains: Entities such as ARROW PHARMACEUTICALS PTY LTD. (Australia) operate extensive pharmacy networks. They procure Quinine to stock their outlets, ensuring availability for consumers. Their orders are typically regular and based on consumer demand patterns, aiming to maintain optimal inventory levels across their retail locations.

5. Re-exporters: Companies like SOBAPS S.A (Benin) may act as re-exporters, importing Quinine for distribution to neighboring countries. Their purchasing behavior involves bulk acquisitions, which are then redistributed, often leveraging regional trade agreements to facilitate cross-border sales.

Each segment's procurement strategies are influenced by their operational roles, market demands, and regulatory environments, leading to varied order sizes and frequencies.

For the top five importing countries, the importation of Quinine is governed by specific regulatory frameworks:

Importers should engage proactively with the respective regulatory authorities to ensure compliance and facilitate the timely importation of Quinine.

The demand for Quinine in importing countries is primarily driven by the prevalence of malaria, a disease for which Quinine remains a critical treatment option. According to the World Health Organization (WHO), in 2024, there were approximately 229 million cases of malaria worldwide, with a significant concentration in sub-Saharan Africa. Countries like Cameroon, Kenya, Madagascar, and Benin, which are among the top importers of Quinine, have high malaria incidence rates, necessitating substantial Quinine procurement to meet treatment needs.

Government healthcare programs and the expansion of universal health coverage further bolster Quinine demand. Many of these countries have national malaria control programs that prioritize the availability of antimalarial medications. Additionally, Quinine's inclusion in the WHO Essential Medicines List underscores its importance, prompting governments and international organizations to procure it through tender-based purchasing mechanisms. The presence of 468 buyers across 93 countries, as per TransData Nexus data, indicates a broad and sustained market for Quinine, reflecting its critical role in global malaria treatment strategies.

The importation of Quinine from India involves a diverse array of buyers, each falling into specific categories:

1. Distributors: Entities like ALLOGA UK (United Kingdom) and PROVET SARLU (Madagascar) function as intermediaries, supplying Quinine to various healthcare providers. Their purchasing patterns are characterized by bulk orders to maintain a steady supply chain, ensuring product availability for their clients.

2. Government Procurement Agencies: Organizations such as UNICEF BANGUI (Central African Republic), UNICEF SOUTH SUDAN (South Sudan), and DIRECTION GENERALE DE LA CAMEBU (Burundi) procure Quinine for national healthcare programs. Their procurement is typically conducted through formal tender processes, emphasizing transparency and cost-effectiveness. These agencies often place large, periodic orders aligned with national health initiatives and budget cycles.

3. Contract Manufacturers: Companies like STRIDES PHARMA UK LTD and STRIDES PHARMA UK LIMITED (both United Kingdom) are involved in the manufacturing and supply of pharmaceutical products. Their procurement of Quinine is likely intended for formulation into finished dosage forms, which are then distributed to various markets. Their purchasing behavior is driven by production schedules and market demand forecasts.

4. Retail Chains: Entities such as ARROW PHARMACEUTICALS PTY LTD. (Australia) operate extensive pharmacy networks. They procure Quinine to stock their outlets, ensuring availability for consumers. Their orders are typically regular and based on consumer demand patterns, aiming to maintain optimal inventory levels across their retail locations.

5. Re-exporters: Companies like SOBAPS S.A (Benin) may act as re-exporters, importing Quinine for distribution to neighboring countries. Their purchasing behavior involves bulk acquisitions, which are then redistributed, often leveraging regional trade agreements to facilitate cross-border sales.

Each segment's procurement strategies are influenced by their operational roles, market demands, and regulatory environments, leading to varied order sizes and frequencies.

For the top five importing countries, the importation of Quinine is governed by specific regulatory frameworks:

Importers should engage proactively with the respective regulatory authorities to ensure compliance and facilitate the timely importation of Quinine.

The demand for Quinine in importing countries is primarily driven by the prevalence of malaria, a disease for which Quinine remains a critical treatment option. According to the World Health Organization (WHO), in 2024, there were approximately 229 million cases of malaria worldwide, with a significant concentration in sub-Saharan Africa. Countries like Cameroon, Kenya, Madagascar, and Benin, which are among the top importers of Quinine, have high malaria incidence rates, necessitating substantial Quinine procurement to meet treatment needs.

Government healthcare programs and the expansion of universal health coverage further bolster Quinine demand. Many of these countries have national malaria control programs that prioritize the availability of antimalarial medications. Additionally, Quinine's inclusion in the WHO Essential Medicines List underscores its importance, prompting governments and international organizations to procure it through tender-based purchasing mechanisms. The presence of 468 buyers across 93 countries, as per TransData Nexus data, indicates a broad and sustained market for Quinine, reflecting its critical role in global malaria treatment strategies.